Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study

Diabetes, Obesity and Metabolism

Volumn 18, Issue 9, 2016, Pages 907-915

  Khunti, K ^a   Alsifri, S ^b   Aronson, R ^c   Cigrovski Berkovic M ^d   Enters Weijnen, C ^e   Forsen T ^f   Galstyan, G ^g   Geelhoed Duijvestijn, P ^h   Goldfracht, M ^i,j   Gydesen, H ^k   Kapur, R ^k   Lalic, N ^l   Ludvik, B ^m   Moberg, E ⁿ   Pedersen Bjergaard, U ^o   Ramachandran, A ^p  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b AL HADA ARMED FORCES HOSPITAL   (Saudi Arabia)

^c LMC DIABETES AND ENDOCRINOLOGY   (Canada)

^d SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY OF HELSINKI   (Finland)

^g ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

^h MEDICAL CENTER HAAGLANDEN   (Netherlands)

ⁱ CLALIT HEALTH SERVICES   (Israel)

^j TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^k NOVO NORDISK A S   (Denmark)

^l UNIVERSITY OF BELGRADE   (Serbia)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ KAROLINSKA INSTITUTE   (Sweden)

^o HILLERØD HOSPITAL   (Denmark)

^p Dr A Ramachandran's Diabetes Hospitals   (India)

more..

Author keywords

diabetes; global; HAT study; hypoglycaemia; insulin; observational

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RUSSIAN FEDERATION; SOUTH AND CENTRAL AMERICA; AGED; CANADA; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EASTERN EUROPE; EUROPE; METABOLISM; MIDDLE AGED; MIDDLE EAST; MULTICENTER STUDY; QUESTIONNAIRE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SOUTHEAST ASIA;

ADULT; AGED; ASIA, SOUTHEASTERN; CANADA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EUROPE; EUROPE, EASTERN; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LATIN AMERICA; MALE; MIDDLE AGED; MIDDLE EAST; PREVALENCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; RUSSIA; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84977080761     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12689     Document Type: Article

References (27)

1. Leiter LA, Boras D, Woo VC. Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals. Can J Diabetes 2014; 38: 38–44.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–1379.
3. Chiang JL, Kirkman MS, Laffel LM, Peters AL, Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37: 2034–2054.
4. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogs vs. NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007: Apr 18;(2):CD005613.
5. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008: 16;(2):CD006739.
6. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogs for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011: 5;(10):CD006423.
7. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir vs. insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011: Jul 6;(7):CD006383.
8. Food and Drug Administration. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention (Draft Guidance). Food Drug Administration, 2008. Available from URL: http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf. Accessed 5 February 2015.
9. Brod M, Wolden M, Christensen T, Bushnell DM. Understanding the economic burden of non-severe nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. Value Health 2013; 16: 1140–1149.
10. Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, Lahtela J, Jensen MM, Ostenson CG. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and well-being in insulin-treated patients with diabetes in seven European countries. J Med Econ 2013; 16: 1453–1461.
11. Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert JM, Pedersen-Bjergaard U. Self-reported non-severe hypoglycemic events in Europe. Diabet Med 2014; 31: 92–101.
12. Luddeke HJ, Sreenan S, Aczel S et al. PREDICTIVE – a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycemia from the European cohort. Diabetes Obes Metab 2007; 9: 428–434.
13. Munro N, Barnett AH. Incidence, worry and discussion about dosing irregularities and self-treated hypoglycemia amongst HCPs and patients with type 2 diabetes: results from the UK cohort of the Global Attitudes of Patient and Physicians (GAPP2) survey. Int J Clin Pract 2014; 68: 692–699.
14. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245–1249.
15. Khunti K, Caputo S, Damci T et al. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab 2012; 14: 1129–1136.
16. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.
17. Miller ME, Bonds DE, Gerstein HC et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated hemoglobin concentration on the risk of severe hypoglycemia: post-hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340: b5444.
18. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.
19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
20. Donnelly LA, Morris AD, Frier BM et al. Frequency and predictors of hypoglycemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749–755.
21. Cariou B, Fontaine P, Eschwege E et al. Frequency and predictors of confirmed hypoglycemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab 2015; 41: 116–125.
22. UK Hypoglycemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140–1147.
23. Edridge C, Dunkley A, Bodicoate D et al. Prevalence and incidence of hypoglycemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS One 2015; 10: e0126427.
24. Elliot L, Aronson R, Galstyan G et al. Health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diabetologia 2015; 58(Suppl. 1): S480 (Abstract 991). Content presented in poster at EASD 2015.
25. Karges B, Rosenbauer J, Kapellen T et al. Hemoglobin A1c levels and risk of severe hypoglycemia in children and young adults with type 1 diabetes from Germany and Austria: a trend analysis in a cohort of 37,539 patients between 1995 and 2012. PLoS Med 2014; 11: e1001742.
26. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51: 724–733.
27. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 2005; 54: 3592–3601.